Summary:
Midwest Research Group is conducting a 6-week, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Efficacy and Safety Study of Dasotraline versus Placebo in Subjects 6 to 12 Years of Age with Attention Deficit Hyperactivity Disorder (ADHD)
Qualified Participants Must:
• Be between 6 and 12 years of age
•
Have a primary diagnosis of ADHD (inattentive, hyperactive, or combined presentation)
•
Be able to swallow capsules
Qualified Participants May Receive:
Compensation for time and travel